再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

交易中 11-10 14:24:30 EST

26.28

-0.58

-2.16%

最高27.19	最低26.15	成交量95.07万
今开26.98	昨收26.86	日振幅3.87%
总市值29.53亿	流通市值25.52亿	总股本1.12亿
成交额2,510万	换手率0.98%	流通股本9,711万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":26.28,"timestamp":1794338666093,"preClose":26.86,"halted":0,"volume":950678,"delay":0,"changeRate":-0.021593447505584448,"floatShares":97110400,"shares":112353700,"eps":-1.780475,"marketStatus":"交易中","change":-0.58,"latestTime":"11-10 14:24:30 EST","open":26.98,"high":27.19,"low":26.15,"amount":25099584.752093997,"amplitude":0.038719,"askPrice":26.41,"askSize":325,"bidPrice":26.25,"bidSize":274,"shortable":3,"etf":0,"ttmEps":-1.780475,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794344400000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":26.86,"preHourTrading":{"tag":"盘前","latestPrice":27.19,"preClose":26.86,"latestTime":"09:29 EST","volume":226844,"amount":6094647.23772,"timestamp":1794320999999,"change":0.33,"changeRate":0.012286,"amplitude":0.167535},"postHourTrading":{"tag":"盘后","latestPrice":27.2239,"preClose":26.86,"latestTime":"19:45 EST","volume":33166,"amount":890911.54,"timestamp":1794271525674,"change":0.3639,"changeRate":0.013548,"amplitude":0.013548},"volumeRatio":0.738957,"impliedVol":0.4848,"impliedVolPercentile":0.243},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2682820601","title":"生物医药板块走强 再鼎医药（09688）涨超13% 全球医药融资回暖支撑创新药与CXO景气上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2682820601","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682820601?lang=zh_cn&edition=full","pubTime":"2026-11-09 10:08","pubTimestamp":1794190084,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，截至发稿，再鼎医药 涨13.07%，康诺亚-B涨7.22%，康方生物涨6.33%，科伦博泰生物涨5.36%，药明生物涨4.96%，金斯瑞生物科技涨4.48%，复宏汉霖涨4.04%。2026年上半年，全球生物科技融资、License交易、并购交易金额分别达到502亿美元、1667亿美元和960亿美元，均显著超越去年上半年，医药融资及License交易持续回暖，为医药研发提供了资金支持。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995489","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","LU0029874061.USD","SG9999002562.SGD","BK4581","02162","159938","LU1242518931.SGD","09939","LU0456846285.SGD","LU2039709279.SGD","02269","02696","399441","BK1610","CXO","IBBQ","09688","06990","LU0516423091.SGD","LU0543330566.HKD","LU0140636845.USD","LU0181495838.USD","XBI","LU0359201612.USD","LU0051755006.USD","KURE","LU1794554557.SGD","LU0196878994.USD","06978","LNGR","LU0456827905.SGD","09926","01548","LU1242518857.USD","WX","BK1583","161726","BK4588","HK0000165453.HKD","LU0320764243.SGD","LU0348767384.USD","LU0348825331.USD","LU0561508036.HKD","MEDX","LU0348784397.USD","159992","LU2476274308.USD","ZLAB","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682277218","title":"再鼎医药早盘涨逾12% 第三季度产品收入1.076亿美元环比增长2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682277218","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682277218?lang=zh_cn&edition=full","pubTime":"2026-11-09 09:50","pubTimestamp":1794189000,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药早盘涨逾12%。截至发稿，股价上涨11.77%，现报20.52港元，成交额5130.878万港元。再鼎医药近日披露2026年第三季度业绩。报告期内，公司总收入为1.082亿美元，其中产品收入净额为1.076亿美元，环比增长2%，主要得益于纽再乐的市场覆盖率和渗透率提升，以及呫诺美林曲司氯铵的上市。2027年将是关键之年，公司有望在美国递交zoci的首个生物制品上市许可申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-09/doc-iniyazcy6374236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4531","ZLAB","BK4585","BK4588","BK1574","BK1588","LU2488822045.USD","BK4526","BK1161","BK4139","09688","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681686076","title":"纳斯达克中国金龙指数涨超1%，禾赛科技涨9.50%，晶科能源涨8.65%，阿特斯涨7.90%，小牛电动涨7.47%，再鼎","url":"https://stock-news.laohu8.com/highlight/detail?id=2681686076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681686076?lang=zh_cn&edition=full","pubTime":"2026-11-06 23:09","pubTimestamp":1793977766,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HXC","BK4091","BK4585","BK4124","BK4531","BK4548","BK4141","NIU","BK4555","LU2476274720.SGD","LU2488822045.USD","BK4139","LU2778985437.USD","HSAI","09688","02525","CSIQ","BK4526","JKS","BK4558","LU2476274308.USD","BK4588","BK4519","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681867114","title":"纳斯达克中国金龙指数涨超0.5%，禾赛科技涨8.33%，再鼎医药涨7.30%，蔚来涨4.38%，晶科能源涨3.21%，小","url":"https://stock-news.laohu8.com/highlight/detail?id=2681867114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681867114?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:37","pubTimestamp":1793975869,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","BK4531","LU2476274308.USD","BK4585","LU2778985437.USD","NIOG","BK4551","BK4588","ZLAB","BK4581","BK4534","XPEG","LU2488822045.USD","HXC","BK4574","NIO","LU0052750758.USD","09688","LU0320764599.SGD","09868","BK4139","LU0708995583.HKD","NIO.SI","02525","BK4526","BK4555","JKS","XPEV","09866","BK4509","LU2476274720.SGD","BK4548","EVS.SI","BK4099","BK4504","BK4532","BK4124","BK4141","HSAI","BK4519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681107880","title":"再鼎医药（09688）盘中涨近2% 三季度产品收入净额环比增长2% 预计明年多个全球项目成为催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2681107880","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681107880?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:13","pubTimestamp":1793931223,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 盘中震荡走高，截至发稿，最新报18.51港元，涨幅1.87%，成交额3121.83万港元。消息面上，公司公告披露，2026年第三季度总收入为1.082亿美元，去年同期为1.161亿美元。公司产品收入净额为1.076亿美元，环比增长2%。期内亏损净额为4,610万美元。研发开支为4,980万美元，SG&A开支为7,010万美元，同比均基本持平。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995400","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","BK4526","BK4588","BK4531","09688","BK1161","BK1588","BK4548","BK4139","BK4585","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681027516","title":"再鼎医药(09688)第三季度总收入达1.082亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681027516","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681027516?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:12","pubTimestamp":1793880765,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)发布公告，2026年第三季度总收入为1.082亿美元，2025年同期为1.161亿美元。2026年第三季度产品收入净额为1.076亿美元，2025年同期为1.154亿美元。产品收入净额环比增长2%，主要得益于纽再乐(受益于市场覆盖率和渗透率的提升)和呫诺美林曲司氯铵(于2026年6月上市)，部分被肿瘤电场治疗因胶质母细胞瘤市场竞争格局变化导致收入下滑所抵销。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg20.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg20.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1519252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4548","BK4526","BK4585","BK1574","BK4531","09688","BK1588","BK1161","BK4139","ZLAB","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681202254","title":"再鼎医药：三季度亏损净额为4,610万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681202254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681202254?lang=zh_cn&edition=full","pubTime":"2026-11-05 20:03","pubTimestamp":1793880237,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4526","BK4585","LU2488822045.USD","BK4139","BK4531","BK4588","BK4548","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198892221","title":"美股异动 | 热门中概股多数上涨，阿里巴巴涨超5%，百度、蔚来涨超4%，拼多多涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198892221","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198892221?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:55","pubTimestamp":1793804106,"startTime":"0","endTime":"0","summary":"11月4日，热门中概股多数上涨，$阿里巴巴(BABA)$涨5.57%，$拼多多(PDD)$涨3.81%，$百济神州(ONC)$涨7.30%，$百度(BIDU)$涨4.27%，$理想汽车(LI)$涨4.38%，$蔚来(NIO)$涨5.49%，$哔哩哔哩(BILI)$涨5.80%，$万国数据(GDS)$涨8.55%，$再鼎医药(ZLAB)$涨5.51%。$京东(JD)$涨3.44%，$小鹏汽车(09868)$涨3.46%，$新东方(EDU)$涨4.41%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/4c11959d4aeba6600bb867b9481130ad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/4c11959d4aeba6600bb867b9481130ad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837565.USD","LU1981816686.USD","BABO","BK4526","CNQQ","LU2211817866.USD","BK7132","YANG","LU0315179316.USD","XPEV","LU0348827113.USD","CLIX","PDD","TTTN","LU1769817179.HKD","LU0561508036.HKD","LU0251143458.SGD","FXI","LU1171460220.USD","LU0287142896.SGD","BK4588","BABX","IE00B3M56506.USD","BK4514","SG9999002463.SGD","LU0738911758.USD","LU0417516902.SGD","LU0228659784.USD","LU0328353924.USD","BK4524","BK4614","HK0000306685.HKD","LU0918141705.HKD","82822","LU0516423091.SGD","LU0633140727.USD","BK4558","BK4548","LU0348825331.USD","EVS.SI","LU0821914370.USD","LU0823039010.USD","IE00BGV7N243.SGD","LU1235295612.USD","LU1251922891.USD","LU2279858448.HKD","LU0307460666.USD","LU0650527681.SGD","BK4563","LU1880383440.USD","KBDU","ONC","LU1823568750.SGD","LU0594300179.USD","KALL","GDS","BK4099","BIDU","LU0871576103.HKD","BK4116","LU0310800965.SGD","KJD","LU1105468828.SGD","BK4585","LU0051755006.USD","LU1770034418.SGD","LU1242518857.USD","ASHR","IE00B0JY6N72.USD","LU0823038988.USD","LU0348788117.USD","MCH","FDNI","LU0173614495.USD","BK4531","LU0072913022.USD","DRAG","PCCE","LU1051768304.USD","LU0963586101.USD","LU1323998911.USD","02843","02015","LU1988902786.USD","ONLN","LU0140636845.USD","LU0052750758.USD","HK0000320223.HKD","NIO.SI","BK4085","BABU","LU1720050803.USD","LU2008162690.USD","09618","NIO","09698","SG9999002828.SGD","BABW","ASHS","09626","BK4555","BABC","LU0949170772.SGD","LU0359201612.USD","CHAU","LU1023057109.AUD","LU0455707207.USD","LU0708995583.HKD","BK4505","06160","LU0320764599.SGD","LU2242644610.SGD","BK1500","IE0008368742.USD","EDZ","KBAB","LU0049112450.USD","BK4504","IE0034224299.USD","LU0067412154.USD","LU0918141887.USD","LU0210526637.USD","DRGN","BK4529","LU1051769294.HKD","LU1008478684.HKD","BK4510","LU0143863784.USD","LU1046421795.USD","LU1956131251.USD","LU0502904849.HKD","BK4607","LU0594300419.USD","LU0880133367.SGD","LU1868837722.USD","LU0456827905.SGD","LU0128525689.USD","BK4579","BK4602","09901","CCPX","BK4220","BK4575","02823","LI","BK4501","LU0327786744.USD","LU0651946864.USD","02822","KPDD","03431","LU1868838027.USD","BK4503","KCAI","LU0572944931.SGD","BK4566","LU0651947912.USD","HXC","IE00B29SXG58.USD","BK6125","SG9999014674.SGD","LU0039217434.USD","BK1161","BK1587","BK1119","LU2087589342.USD","IE00BF5LJ272.USD","BK4565","LU0545039389.USD","LU2177674079.SGD","BK4139","LU0878005551.USD","LU1719994722.HKD","HK0000320264.USD","KWEB","BK4077","LU0235996351.USD","BK4533","YINN","BK4535","BK4543","BK4612","LU0348814723.USD","LU0661504455.SGD","BK4509","BK1588","BK4581","LU0072462343.USD","ALBmain","LU0117841782.USD","BABA","BK4506","ZLAB","EDU","09688","LU0553294199.USD","BK4122","LU1235294995.USD","LU1794554557.SGD","LU2264538146.SGD","BK4527","BK1610","LU0259732245.USD","KURE","LU1282648689.USD","LU0359201885.HKD","LU2328871848.SGD","LU0516422366.SGD","NIOG","LU0683595622.HKD","LU0823426308.USD","09866","XPP","LU1064131342.USD","BK4532","LU2488822045.USD","CWEB","LU0047713382.USD","LU0593848301.USD","LU0588546209.SGD","JD","LU1242518931.SGD","LU1880383366.USD","LU0456842615.SGD","LU1048588211.SGD","LU0370786039.SGD","LU0348816934.USD","IEMG","LU2257852520.SGD","LU1046422090.SGD","LU0531971595.HKD","LU2399975544.HKD","LU0164865239.USD","HK0000306701.USD","82843","LU0640798160.USD","LU0828237510.HKD","BK4513","LU0605514214.HKD","BK1539","BK4204","LU2226246903.HKD","IE00BFMHRM44.USD","BK1575","EDU.AU","LU1688375341.USD","LU0348805143.USD","LU0589944569.HKD","LU1969619763.USD","LU1303224171.USD","LU0231483743.USD","BK4574","LU0823397103.USD","LU1152091754.HKD","YXI","BK4551","LU0823413587.USD","LU0106959298.USD","LU1003077747.HKD","BK4550","LU0823413660.USD","BK1574","BIDG","BK4554","HK0000165453.HKD","BK4577","LU2039709279.SGD","LU0823397285.USD","LU1188198961.HKD","CQQQ","LU1048596156.SGD","LU0501845795.SGD","BK1583","LU0326950275.SGD","FXP","SG9999002562.SGD","LU1515016050.SGD","LU0052756011.USD","LU0979878070.USD","IDRV","LU0516422440.USD","PDDL","09868","LU0516422952.EUR","BK4538","FLCH","JCHI","LU0823426480.USD","LU0143863198.USD","LU1808992512.USD","BBYY","LU1769817096.USD","BK4534","LU0633140560.USD","LU0048580855.USD","LU0329678170.USD","LU1961090484.USD","LU1115378108.SGD","LU1152091168.USD","IE0031814852.USD","BK4587","LU0797268264.HKD","LU0244354667.USD","MCHI","NBCE","LU0456846285.SGD","LU1267930227.SGD","BILI","09988","82823","LU0329678337.USD","BK4502","LU0359202008.SGD","LU2148611432.USD","LU0737861772.HKD","LU0516423174.USD","LU0463099449.HKD","BK4552","BK4553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680897580","title":"再鼎医药盘中涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680897580","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680897580?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:03","pubTimestamp":1793772180,"startTime":"0","endTime":"0","summary":"11月4日，再鼎医药(09688.HK)盘中涨超5%，截至13时58分，涨5.45%，报17.790港元/股，成交额4795.79万港元。消息面上，2026年欧洲肿瘤内科学会年会当日启幕，29项中国创新药研究入选突破性摘 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261104/c681449374.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261104/c681449374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4531","BK4548","BK4585","BK4139","LU2488822045.USD","BK1574","BK1161","BK4526","BK4588","ZLAB","BK1588","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678928974","title":"再鼎医药：10月28日发行新股1.13亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678928974","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678928974?lang=zh_cn&edition=full","pubTime":"2026-10-28 23:26","pubTimestamp":1793201160,"startTime":"0","endTime":"0","summary":"南财智讯10月28日电，再鼎医药（09688.HK）发布翌日披露报表，10月28日，公司配售及发行1.13亿股新股份，作为向投资者发行及出售的美国存托股份的相关股份，每股发行价为17.28港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283912733380.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283912733380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1574","BK4588","BK1161","BK4526","BK4139","BK4531","BK4548","09688","BK1588","BK4585","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678103259","title":"“基石疗法”潜力获高度认可，再鼎医药(09688) zoci持续拓展未来价值边界","url":"https://stock-news.laohu8.com/highlight/detail?id=2678103259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678103259?lang=zh_cn&edition=full","pubTime":"2026-10-27 21:48","pubTimestamp":1793108908,"startTime":"0","endTime":"0","summary":"在此背景下，再鼎医药携Zoci一线治疗小细胞肺癌的最新研究成果亮相今年ESMO年会，无疑成为业界关注的焦点。这也是双药方案成为后续开发重点的原因。据智通财经APP了解，再鼎医药计划于2027年向美国FDA递交Zoci的首个适应症的上市申请。若进展顺利，Zoci有望成为全球首个获批的DLL3 ADC。能否成为小细胞肺癌一线的\"基石疗法\"，最终要靠三期的总生存数据来回答。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU2488822045.USD","BK1161","ZLAB","BK4526","BK4588","09688","BK4531","BK4139","BK4548","BK4585","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678778130","title":"再鼎医药（09688）涨超5% ZOCI一线小细胞肺癌1b期数据亮眼 将启动全球随机3期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2678778130","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678778130?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:55","pubTimestamp":1792979713,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 盘初股价上扬，最新涨5.29%，报18.72港元，成交额3529万港元。消息面上，再鼎医药于2026年10月23日公布zocilurtatug pelitecan联合阿替利珠单抗用于广泛期小细胞肺癌一线治疗的全球1b期临床研究首个数据。在推荐3期研究剂量1.6 mg/kg下，zoci联合阿替利珠单抗的经确认客观缓解率达81.8%，6个月无进展生存率为81.9%。该双药方案耐受性良好，与zoci相关的3级及以上不良事件发生率为9.1%。基于此数据，公司预计于2026年底前启动全球随机3期研究。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994403","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2488822045.USD","BK4139","BK1574","BK4588","BK4531","BK4526","BK1588","BK1161","BK4548","09688","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678130196","title":"再鼎医药盘中涨超7% zoci联合阿替利珠单抗用于ES-SCLC一线治疗的相关临床数据亮相ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2678130196","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678130196?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:41","pubTimestamp":1792978860,"startTime":"0","endTime":"0","summary":"模拟交易客户端再鼎医药盘中涨超7%，截至发稿，股价上涨5.91%，现报18.83港元，成交额3242.179万港元。10月23日，再鼎医药发布公告，公司公布一项评估zocilurtatug pelitecan联合阿替利珠单抗用于广泛期小细胞肺癌一线治疗的全球1b期临床研究的首个数据。该数据将在于西班牙马德里举行的欧洲肿瘤内科学会2026年大会上公布。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-10-26/doc-iniwpfmw2511599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4548","ZLAB","BK4531","LU2488822045.USD","BK1574","BK4588","09688","BK4526","BK1588","BK4585","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677976895","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2677976895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677976895?lang=zh_cn&edition=full","pubTime":"2026-10-23 23:40","pubTimestamp":1792770042,"startTime":"0","endTime":"0","summary":"消息面上，10月23日，再鼎医药公布了旗下在研抗体偶联药物Zocilurtatug Pelitecan用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。安全性方面，在上述33例接受双药治疗的患者中，与Zoci相关的3级及以上不良事件发生率为9.1%。再鼎医药表示，上述研究结果支持进一步探索以ADC联合免疫治疗替代传统含铂化疗的治疗方案。公司计划于2026年底前启动一项全球随机Ⅲ期临床研究，评估Zoci联合免疫治疗用于广泛期小细胞肺癌一线治疗的疗效与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4526","BK4585","BK4588","09688","ZLAB","BK4139","BK1161","BK4531","LU2488822045.USD","BK4548","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677397689","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾2% 在研ADC ZociⅠb期数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2677397689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677397689?lang=zh_cn&edition=full","pubTime":"2026-10-23 23:40","pubTimestamp":1792770042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4548","BK4526","BK4585","BK4588","ZLAB","BK4139","LU2488822045.USD","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677922196","title":"再鼎医药Zoci一线小细胞肺癌数据支持推进全球三期研究 探索以ADC替代含铂化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2677922196","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677922196?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:07","pubTimestamp":1792757220,"startTime":"0","endTime":"0","summary":"10月23日，再鼎医药有限公司（以下简称“再鼎医药”）公布了旗下在研抗体偶联药物（ADC）ZocilurtatugPelitecan（以下简称“Zoci”，原代号ZL-1310）用于一线广泛期小细胞肺癌的全球Ⅰb期临床研究数据。相关结果将于10月26日在2026年欧洲肿瘤内科学会（ESMO）大会上展示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233906538190.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233906538190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","LU2488822045.USD","BK1588","BK1574","BK4588","ZLAB","09688","BK4548","BK4526","BK4531","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677248139","title":"再鼎医药(09688.HK)：Zocilurtatug Pelitecan(Zoci，前称ZL-1310)在一线广泛期小细胞肺癌中展现出高缓解率、令人鼓舞的持久性及耐受良好的安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=2677248139","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677248139?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:50","pubTimestamp":1792756207,"startTime":"0","endTime":"0","summary":"格隆汇10月23日丨再鼎医药公告，中国上海和美国马萨诸塞州剑桥市—2026年10月23日—再鼎医药有限公司，一家以创新为驱动的全球生物制药公司，今日公布了一项评估zocilurtatug pelitecan联合阿替利珠单抗用于广泛期小细胞肺癌一线治疗的全球1b期临床研究的首个数据。\"公司在这一不含化疗的标准方案中所观察到的确认的高缓解率和令人鼓舞的持久性及耐受良好的安全性特征尤为出色。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261023/32406819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","09688","BK1574","BK1588","LU2488822045.USD","ZLAB","BK4139","BK4531","BK4585","BK4526","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677917202","title":"港股异动丨再鼎医药一度跌超6%，配股筹逾19亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677917202","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677917202?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:17","pubTimestamp":1792732642,"startTime":"0","endTime":"0","summary":"港股市场再鼎医药(9688.HK)一度跌超6%，报16.71港元，股价创8月7日以来新低。消息面上，再鼎医药公布，与投资者订立证券购买协议，配售1134万股美国存托股份(ADS)，作价每股22.04美元，相当约17.28港元，较港股昨日收市折让约3.14%，集资约2.5亿美元(约19.49亿港元)。公司指出，拟将所得款项净额主要用于支持其Delta样配体3(DLL3)抗体偶联药物(ADC)靶向Zocilurtatug Pelitecan(zoci)的持续全球开发。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202610/23/20261023181068.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202610/23/20261023181068.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261023/32406243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2488822045.USD","BK4531","BK4526","BK1574","BK1161","BK1588","KCAI","BK4548","BK4588","VXUS","ZLAB","BK4139","BK4585","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916314","title":"再鼎医药：私人配售美国存托股份净筹2.41亿美元 用于DLL3 ADC药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916314","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916314?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:25","pubTimestamp":1792718700,"startTime":"0","endTime":"0","summary":"10月23日，再鼎医药（09688/ZLAB）发布公告，公司于2026年10月22日与投资者签订了证券购买协议，计划通过私人配售向投资者发行和出售合共1134万股美国存托股份，代表合计面值为680.4美元的1.13亿股相关股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610233905143872.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610233905143872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1161","BK1588","ZLAB","BK4588","BK4548","LU2488822045.USD","BK1574","BK4526","09688","BK4585","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677509913","title":"再鼎医药（09688）拟发行1134万股美国存托股份 较港股近5日平均收市价约折让6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677509913","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677509913?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:40","pubTimestamp":1792716003,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 发布公告，于2026年10月22日，公司与投资者订立证券购买协议，据此，公司同意按美国存托股份价格向投资者发行及出售合共11,340,000股美国存托股份，约为于本公告日期现有已发行普通股约9.97%；及经配发及发行相关股份扩大后已发行普通股约9.06%。每股美国存托股份代表十股普通股作为相关股份。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NjM1YWNhMGUzZGNhNThhMTg4MzM5MDkyOTUwOA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NjM1YWNhMGUzZGNhNThhMTg4MzM5MDkyOTUwOA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","BK4526","BK1588","BK4139","BK4531","BK4585","BK4588","BK1161","09688","VXUS","LU2488822045.USD","BK1574","KCAI","BK4548"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.2398},{"period":"1month","weight":0.0748},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.3122},{"period":"1year","weight":0.2265},{"period":"ytd","weight":0.5227}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.02394},{"month":5,"riseRate":0.444444,"avgChangeRate":0.004882},{"month":6,"riseRate":0.555556,"avgChangeRate":0.07528},{"month":7,"riseRate":0.444444,"avgChangeRate":0.000111},{"month":8,"riseRate":0.666667,"avgChangeRate":0.044305},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.045569},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058929},{"month":11,"riseRate":0.6,"avgChangeRate":0.112982},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}